Last reviewed · How we verify
simmitinib plus irinotecan liposome
At a glance
| Generic name | simmitinib plus irinotecan liposome |
|---|---|
| Sponsor | Shanghai Runshi Pharmaceutical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (PHASE1, PHASE2)
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |